The cystic fibrosis transmembrane conductance regulator as a biomarker in non-small cell lung cancer

Adult Male Mice, Inbred BALB C Epithelial-Mesenchymal Transition Lung Neoplasms Blotting, Western Cystic Fibrosis Transmembrane Conductance Regulator Down-Regulation Mice, Nude Kaplan-Meier Estimate Middle Aged Immunohistochemistry Disease-Free Survival 3. Good health Mice 03 medical and health sciences 0302 clinical medicine Carcinoma, Non-Small-Cell Lung Biomarkers, Tumor Animals Humans Female Aged
DOI: 10.3892/ijo.2015.2921 Publication Date: 2015-03-06T13:33:14Z
ABSTRACT
An increased risk of non-small cell lung cancer (NSCLC) in cystic fibrosis (CF) patients and carriers CF transmembrane conductance regulator (CFTR) mutations has been proposed. However, the role CFTR remains controversial. In present study, expression was assessed 165 NSCLC tumors 22 normal samples with validation an independent series 131 samples. The effect gain loss on malignant behavior examined. manipulation tumor metastasis examined a mouse model. Expression downregulated (p=0.041). Low correlated advanced stage (p<0.001) lymph node (p=0.009). significantly associated poor prognosis (overall survival: 45 vs. 36 months, p<0.0001; progression-free 41 30 p=0.007). Knockdown cells enhanced (epithelial-mesenchymal transition, invasion migration); contrast, overexpression suppressed progression vitro vivo. tumor-suppressing inhibition multiple uPA/uPAR-mediated traits culture. These results show that plays suggest may serve as novel indicator for predicting adverse patients.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (38)
CITATIONS (43)